Compare Fiverr International Ltd (FVRR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Novartis AG — how do they compare? Fiverr International Ltd trades at $11.48 (market cap $404.45M), while Novartis AG trades at $151.84 (market cap $287.66B). The key difference: Novartis AG is far larger — about 711.2× Fiverr International Ltd's market cap, and Novartis AG pays a 3.14% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | NVS | |
|---|---|---|
Market Cap | $404.45M | $287.66B |
Sector | Industrials | Health |
52-Week High | $26.67 | $168.62 |
52-Week Low | $9.62 | $113.50 |
Enterprise Value | $135.05M | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.07, down 1.77% on the day, with a bullish technical signal from moving averages. The company reported revenue of $430.91M in 2025, with net income of $20.98M and improving profit margins. Recent earnings show a mix of beats and one miss, with Q2 2026 results expected soon. Analyst sentiment is mixed, with 41.18% buy ratings and no sell ratings.
The outlook hinges on execution of its strategy shift amid competitive pressures. Risks include declining active buyers and a pending legal investigation. Upside potential exists if spending per buyer growth continues and the company returns to consistent earnings beats, but investor caution is warranted near the 52-week low.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
